Qyuns Therapeutics Co (HKSE:02509) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02509 Qyuns Therapeutics Co Ltd HKSE:02509
9 GF Score
Price HK$17.64
! 5 Warning Signs
View Full Analysis

What is Qyuns Therapeutics Co FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:02509
9GF Score
Qyuns Therapeutics Co Ltd HKSE:02509
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Qyuns Therapeutics Co Business Description

Address No. 907 Yaocheng Avenue, Room 1310, Building 1, Taizhou, Jiangsu, CHN
Qyuns Therapeutics Co Ltd is a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory, and digestive diseases. The group is principally engaged in the research and development, manufacturing, and commercialisation of biologic therapies for autoimmune and allergic diseases. Key revenue is generated from the PRC.
9GF Score

Get the complete analysis for HKSE:02509

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$17.64
Price